Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALN-4915 in Adult Healthy Volunteers
NCT07535606Phase 1Active, not recruiting
- Sponsor
- Alnylam Pharmaceuticals
- Start
- Mar 2026
- Primary completion
- Jul 2027
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial comparing ALN-4915 with Placebo (2 arms). Primary endpoint: Frequency of Adverse Events at Month 12. Started Mar 2026; status: active, not recruiting.
02
Drugs
ALN-4915
Beyond the preview
Go deeper on NCT07535606.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07535606.